Volume 17, Number 6—June 2011
Salmonella enterica Serotype Typhi with Nonclassical Quinolone Resistance Phenotype
Highlight and copy the desired format.
|EID||Accou-Demartin M, Gaborieau V, Song Y, Roumagnac P, Marchou B, Achtman M, et al. Salmonella enterica Serotype Typhi with Nonclassical Quinolone Resistance Phenotype. Emerg Infect Dis. 2011;17(6):1091-1094. https://dx.doi.org/10.3201/eid1706.101242|
|AMA||Accou-Demartin M, Gaborieau V, Song Y, et al. Salmonella enterica Serotype Typhi with Nonclassical Quinolone Resistance Phenotype. Emerging Infectious Diseases. 2011;17(6):1091-1094. doi:10.3201/eid1706.101242.|
|APA||Accou-Demartin, M., Gaborieau, V., Song, Y., Roumagnac, P., Marchou, B., Achtman, M....Weill, F. (2011). Salmonella enterica Serotype Typhi with Nonclassical Quinolone Resistance Phenotype. Emerging Infectious Diseases, 17(6), 1091-1094. https://dx.doi.org/10.3201/eid1706.101242.|
We report Salmonella enterica serotype Typhi strains with a nonclassical quinolone resistance phenotype (i.e., decreased susceptibility to ciprofloxacin but with susceptibility to nalidixic acid) associated with a nonsynonymous mutation at codon 464 of the gyrB gene. These strains, not detected by the nalidixic acid disk screening test, can result in fluoroquinolone treatment failure.
Typhoid fever caused by Salmonella enterica serotype Typhi (hereafter referred to as Salmonella Typhi) remains a major health problem in the developing world (1). Treatment with appropriate antimicrobial drugs has become hampered by gradual plasmid-mediated resistance to ampicillin, chloramphenicol, and cotrimoxazole, particularly in southern and Southeast Asia (2). Consequently, since the early 1990s, fluoroquinolones (such as ofloxacin and ciprofloxacin [Cip]) have been widely used. However, multidrug-resistant Salmonella Typhi isolates that are also resistant to nalidixic acid (NalR) (MIC >256 μg/mL) and show decreased susceptibility to Cip (CipDS) (MIC range, 0.125 μg/mL–1 μg/mL) have emerged and become endemic on the Indian subcontinent and in Southeast Asia (3–5). This resistance to quinolones was caused by amino acid substitutions in the quinolone resistance–determining region (QRDR) of the DNA gyrase subunit gyrA, a key target of quinolones. Because these NalR–CipDS Salmonella Typhi strains have been associated with slower clinical responses to fluoroquinolones and treatment failures, clinical laboratories should attempt to identify these isolates (3,6,7). However, despite the accumulation of clinical, microbiologic, and pharmacokinetic–pharmacodynamic studies suggesting a resistance breakpoint of >0.125 μg/mL for ciprofloxacin, the clinical breakpoints published by the Clinical and Laboratory Standards Institute (CLSI) (susceptibility <1 μg/mL, resistance >4 μg/mL) and those from the antibiogram committee of the French Society for Microbiology (susceptibility <0.5 μg/mL, resistance >1 μg/mL) (www.sfm.asso.fr/nouv/general.php?pa=2) have not been reevaluated (6–9). Use of these standard breakpoints has probably resulted in the underreporting of CipDS Salmonella Typhi strains. The NalR screening test has been proposed as an alternative since the mid–1990s and recommended since 2004 by CLSI and 2010 by the French Society for Microbiology (3,7). This screening test is based on the fact that CipDS Salmonella Typhi isolates with nonsynonymous (NS) mutations in codons 83 or 87 of gyrA are uniformly NalR. However, recent reports have indicated that this approach cannot identify the newly described Salmonella Typhi isolates that are Nal susceptible (NalS)–CipDS for which mechanisms of resistance are not linked to mutations in gyrA (7,10,11). Recently, NS mutations in codons 464 (Ser to Phe) and 466 (Glu to Asp) of gyrB were found in 7 NalS–CipDS Salmonella Typhi isolates (12). We present data on the occurrence and characterization of the resistance mechanisms of NalS–CipDS isolates in 685 Salmonella Typhi isolates of the French National Reference Center for Salmonella (FNRC-Salm).
In France, laboratory surveillance of typhoid fever infections is performed by the FNRC-Salm through its network of ≈1,500 hospital and private clinical laboratories. Almost all Salmonella Typhi isolates in France are referred to the FNRC-Salm, and almost all are acquired abroad, mainly in Africa and Asia. Until 2009, CipDS Salmonella Typhi was monitored with the 30-μg Nal screening test. A total of 685 Salmonella Typhi isolates collected during 1997–2009 were reanalyzed to identify NalS–CipDS Salmonella Typhi isolates. The scattergram correlating the zone diameters around the 5-μg ciprofloxacin disk with those of the 30-μg Nal disk showed 4 subpopulations, which were labeled A (554 isolates), B (11 isolates), C (119 isolates), and D (1 isolate) (Figure 1). The characteristics of these populations are shown in Table 1 and Table 2. The QRDRs of gyrA, gyrB, parC, and parE genes were studied on 133 isolates selected to represent diversity in terms of year of isolation, geographic origin, and MICs. To analyze the isolate characteristics, we used the following approaches: sequencing (5), denaturing high performance liquid chromatography (4), and Luminex-based genotyping assays (12). QRDR DNA sequences were compared with those of Salmonella Typhi strain Ty2 (GenBank accession no. AE014613). In subpopulation A, 75 isolates had wild-type QRDR sequences, whereas 2 isolates had a gyrB mutation at codon 465 leading to amino acid substitution Gln to Leu. Their Nal MICs were 2 and 4 μg/mL, respectively, and those of Cip were 0.04 μg/mL and 0.08 μg/mL, respectively. Notably, both isolates were acquired in Mexico during 1998 and 2009, respectively. In subpopulation C, the lowest MIC values for Cip (0.06 μg/mL) were associated with a mutation at codon 87 of the gyrA gene, whereas MICs did not increase with the additional mutation in the parE gene. Subpopulation D consisted of 1 isolate, highly resistant to ciprofloxacin, which was acquired by a traveler in India in 2004. This isolate contained 2 NS mutations in the gyrA gene and 1 in the parC gene.
Eleven isolates of subpopulation B were categorized as susceptible to Nal by determining MICs and by using CLSI breakpoints (susceptibility, <16 μg/mL; resistance, >32 μg/mL). Of the 11 isolates, 8 (from 7 patients) had a ciprofloxacin MIC >0.125 μg/mL and were thus classified as CipDS isolates. We were able to review the medical records of 2 patients infected with a NalS–CipDS isolate. One patient (isolates 08-7675 and 09-1986) relapsed 15 days after completion of the treatment (oral ofloxacin, 200 mg 2×/d for 8 days) (13). The second patient (isolate 05-2556) was treated with extended-spectrum cephalosporins, and no fluoroquinolones. Regarding the resistance mechanisms the plasmid-mediated quinolone resistance–conferring genes qnr (qnrA, B, S, D), qepA, and aac(6′)-Ib-cr were not detected by PCR (5,14). The QRDRs of gyrA, parC, and parE genes were of a wild type, whereas an NS mutation was found in gyrB for all but 1 isolate. However, only the 8 isolates with mutations at codon 464 were NalS–CipDS. To assess whether these isolates were genetically related, haplotyping (4) and XbaI-pulsed-field gel electrophoresis (PFGE) subtyping (5) were performed. On the strength of the results, we concluded that the gyrB mutation was acquired independently by strains belonging to different PFGE types (Figure 2). According to a newly developed single nucleotide polymorphism assay (Y.S.), 2 of these strains belong to the current emerging H58 Asian population (4), whereas the others do not (Table 2). In our study, the NalS–CipDS isolates with gyrB mutations at codon 464 were most often non–multidrug-resistant and acquired mainly in India. Our first NalS–CipDS isolate was isolated 13 years ago, and since is rare (prevalence ≈1%.). Although Cooke et al. (10) did not characterize isolates for their resistance mechanisms, they reported that NalS–CipDS represented 11.6% (49/421) of Salmonella Typhi isolated in England, Scotland, and Wales during 1999–2003, while Lynch et al. (11) reported that such isolates were 4.6% (36/770) of Salmonella Typhi isolates identified in the United States during 1999–2006. Epidemiologic data were available for 39 isolates in the British study, 18 of which were acquired in India, 8 in Pakistan, and 4 in Bangladesh (10). The 10-fold difference in the prevalence observed between our study and that of Cooke et al. are probably related to the historical links and the subsequent population flow between the United Kingdom and the Indian subcontinent.
NalS–CipDS Salmonella Typhi isolates originating from Asia comprise ≈1% of Salmonella Typhi isolates in France but are more prevalent in the United States and the United Kingdom. The NS gyrB mutation at codon 464 was found exclusively in NalS–CipDS isolates; however, the effects of this mutation need to be formally demonstrated by site-directed mutagenesis. Furthermore, the involvement of an efflux system, such as AcrAB-TolC and OqxA, or the qnrC gene, have not been investigated and cannot be excluded.
Whatever the molecular mechanism of resistance of such strains, the main concern is detection of such isolates in clinical practice to prevent fluoroquinolone treatment failures. Consequently, the NalR screening test should no longer be recommended and ciprofloxacin drug MICs should be determined for all Salmonella Typhi isolates instead. There is also a clear need to reevaluate the clinical breakpoints for this pathogen.
We thank all the corresponding laboratories of the French National Reference Center for Salmonella network for their assistance.
This work was funded by the Institut Pasteur (M.A.-D., F.-X.W.), the Institut de Veille Sanitaire (M.A.-D., F.-X.W.), and the Science Foundation of Ireland (grant no. 05/FE1/B882 to Y.S. and M.A.).
- Crump JA, Mintz ED. Global trends in typhoid and paratyphoid fever. Clin Infect Dis. 2010;50:241–6.
- Wain J, Kidgell C. The emergence of multidrug resistance to antimicrobial agents for the treatment of typhoid fever. Trans R Soc Trop Med Hyg. 2004;98:423–30.
- Wain J, Hoa NT, Chinh NR, Vinh H, Everett MJ, Diep TS, Quinolone-resistant Salmonella typhi in Vietnam: molecular basis of resistance and clinical response to treatment. Clin Infect Dis. 1997;25:1404–10.
- Roumagnac P, Weill FX, Dolecek C, Baker S, Brisse S, Chinh NT, Evolutionary history of Salmonella Typhi. Science. 2006;314:1301–4.
- Le TA, Fabre L, Roumagnac P, Grimont PA, Scavizzi MR, Weill FX. Clonal expansion and microevolution of quinolone-resistant Salmonella enterica serotype Typhi in Vietnam from 1996 to 2004. J Clin Microbiol. 2007;45:3485–92.
- Aarestrup FM, Wiuff C, Mølbak K, Threlfall EJ. Is it time to change fluoroquinolone breakpoints for Salmonella spp.? Antimicrob Agents Chemother. 2003;47:827–9.
- Crump JA, Kretsinger K, Gay K, Hoekstra RM, Vugia DJ, Hurd S, Clinical response and outcome of infection with Salmonella enterica serotype Typhi with decreased susceptibility to fluoroquinolones: a United States FoodNet Multicenter Retrospective Cohort Study. Antimicrob Agents Chemother. 2008;52:1278–84.
- Crump JA, Barrett TJ, Nelson JT, Angulo FJ. Reevaluating fluoroquinolone breakpoints for Salmonella enterica serotype Typhi and for non-Typhi salmonellae. Clin Infect Dis. 2003;37:75–81.
- Booker BM, Smith PF, Forrest A, Bullock J, Kelchlin P, Bhavnani SM, Application of an in vitro infection model and simulation for reevaluation of fluoroquinolone breakpoints for Salmonella enterica serotype Typhi. Antimicrob Agents Chemother. 2005;49:1775–81.
- Cooke FJ, Day M, Wain J, Ward LR, Threlfall EJ. Cases of typhoid fever imported to England, Scotland and Wales (2000–2003). Trans R Soc Trop Med Hyg. 2007;101:398–404.
- Lynch MF, Blanton EM, Bulens S, Polyak C, Vojdani J, Stevenson J, Typhoid fever in the United States, 1999–2006. JAMA. 2009;302:859–65.
- Song Y, Roumagnac P, Weill FX, Wain J, Dolecek C, Mazzoni CJ, A multiplex single nucleotide polymorphism typing assay for detecting mutations that result in decreased fluoroquinolone susceptibility in Salmonella enterica serovars Typhi and Paratyphi A. J Antimicrob Chemother. 2010 Jun 1. PMID: 20511368
- Gaborieau V, Weill FX, Marchou B. Salmonella enterica serovar Typhi with decreased susceptibility to ciprofloxacin: a case report [in French]. Med Mal Infect. 2010;40:691–5.
- Sjölund-Karlsson M, Howie R, Rickert R, Krueger A, Tran TT, Zhao S, Plasmid-mediated quinolone resistance among non-Typhi Salmonella enterica isolates, USA. Emerg Infect Dis. 2010;16:1789–91.
TablesCite This Article
- Page created: August 03, 2011
- Page last updated: August 03, 2011
- Page last reviewed: August 03, 2011
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)